Drug Approval | April 17, 2026
Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
The goal is to better support drug developers as programs move from laboratory research into clinical trials
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Subscribe To Our Newsletter & Stay Updated
